These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38687306)

  • 1. Complete Response to Immunotherapy Using Pembrolizumab in a Patient With Conjunctival Squamous Cell Carcinoma With Nodal Metastasis.
    Fan J; Goldberg H; Torres-Cabala CA; Stewart J; Nagarajan P; Debnam M; Crouse EC; Lu T; Ferrarotto R; Esmaeli B
    Ophthalmic Plast Reconstr Surg; 2024 Sep-Oct 01; 40(5):e171-e174. PubMed ID: 38687306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for Conjunctival Squamous Cell Carcinoma with Orbital Extension.
    Demirci H; Elner VM; Demirci FY; Robinson DR; Chinnaiyan A; Schlachter D; Joseph S; Worden F
    Ophthalmology; 2021 May; 128(5):801-804. PubMed ID: 32980395
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
    Sagiv O; Thakar SD; Kandl TJ; Ford J; Sniegowski MC; Hwu WJ; Esmaeli B
    JAMA Ophthalmol; 2018 Nov; 136(11):1236-1241. PubMed ID: 30352118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resolution of advanced conjunctival squamous cell carcinoma with cemiplimab immunotherapy, IFNα-2b, and retinoic acid treatment over 2 years of follow-up.
    Rawlyk B; Karunatilake M; Iqbal M; Eidsness R
    Can J Ophthalmol; 2024 Oct; 59(5):e641-e643. PubMed ID: 38593982
    [No Abstract]   [Full Text] [Related]  

  • 5. Pembrolizumab in recurrent advanced cervical squamous carcinoma.
    Martínez P; Del Campo JM
    Immunotherapy; 2017 May; 9(6):467-470. PubMed ID: 28399693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series.
    Finger PT; Pavlick AC
    J Immunother Cancer; 2019 Mar; 7(1):83. PubMed ID: 30909967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
    Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
    Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
    Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
    Front Immunol; 2021; 12():608292. PubMed ID: 34135884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder.
    Kao C; McNamara M; Alley C; Spector N; Jauhari S; Gupta RT; Zhang T; Zhu J
    Clin Genitourin Cancer; 2019 Jun; 17(3):e672-e677. PubMed ID: 31097390
    [No Abstract]   [Full Text] [Related]  

  • 10. Histologic transformation of lung cancer during pembrolizumab therapy: A case report.
    Si X; You Y; Zhang X; Wang H; Wang M; Zhang L
    Thorac Cancer; 2020 Mar; 11(3):793-796. PubMed ID: 31944570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population.
    Chen WC; Chu PY; Lee YT; Lu WB; Liu CY; Chang PM; Yang MH
    Medicine (Baltimore); 2017 Dec; 96(52):e9519. PubMed ID: 29384959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of trichilemmal carcinoma with distant metastasis using pembrolizumab: a case report and review.
    Liu L; Long T; Wei N; Zhang H; Tang C; Gao J
    Immunotherapy; 2024; 16(10):659-667. PubMed ID: 39259509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic porocarcinoma achieving complete radiological and clinical response with pembrolizumab.
    Lee KA; Cioni M; Robson A; Bataille V
    BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31492726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local and Regional Spread of Primary Conjunctival Squamous Cell Carcinoma.
    Desai SJ; Pruzan NL; Geske MJ; Jeng BH; Bloomer MM; Vagefi MR
    Eye Contact Lens; 2018 Sep; 44 Suppl 1():S312-S315. PubMed ID: 27058828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD-L1: A case report.
    Hamai K; Tanahashi H; Ueno S; Konishi H; Matsumura M; Nomura A; Nakamoto K; Isoyama S; Tanimoto T; Shoda H; Ishikawa N
    Thorac Cancer; 2020 Jun; 11(6):1716-1719. PubMed ID: 32291904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab-induced pancytopenia in a patient with squamous cell lung cancer.
    Ueki Y; Suzuki M; Horikawa Y; Watanabe H; Yamaguchi Y; Morita C; Tsukada A; Takumida H; Kusaba Y; Katsuno T; Tsujimoto Y; Sakamoto K; Hashimoto M; Terada J; Ishii S; Takasaki J; Naka G; Iikura M; Izumi S; Takeda Y; Hojo M; Sugiyama H
    Thorac Cancer; 2020 Sep; 11(9):2731-2735. PubMed ID: 32767641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab for Recurrent Conjunctival Melanoma.
    Kini A; Fu R; Compton C; Miller DM; Ramasubramanian A
    JAMA Ophthalmol; 2017 Aug; 135(8):891-892. PubMed ID: 28715523
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical Response With Pembrolizumab for Cutaneous Squamous Cell Carcinoma.
    Corbett M; Tohani S; Ramli R; O'Duffy F
    JAMA Otolaryngol Head Neck Surg; 2024 Jun; 150(6):524-525. PubMed ID: 38602669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor: A case report and literature review.
    Song W; Wang H; Tian Y; Liu S; Chen X; Cui J; Zhao Y
    Medicine (Baltimore); 2020 Mar; 99(10):e19440. PubMed ID: 32150096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.
    Ott PA; Piha-Paul SA; Munster P; Pishvaian MJ; van Brummelen EMJ; Cohen RB; Gomez-Roca C; Ejadi S; Stein M; Chan E; Simonelli M; Morosky A; Saraf S; Emancipator K; Koshiji M; Bennouna J
    Ann Oncol; 2017 May; 28(5):1036-1041. PubMed ID: 28453692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.